Skip to main content

Adolescent Peak Pruritus NRS Efficacy Results

In the treatment of adolescents (12-17 years) with uncontrolled moderate-to-severe atopic dermatitis

Significant itch relief

Itch results in AD-15261

AD-1526 12-17 YEARS

Definitive conclusions cannot be made for time points earlier than Week 16 as those data were not multiplicity controlled and P value was nominal.

Adolescents ≥60 kg received DUPIXENT 300 mg Q2W after a 600 mg loading dose, and adolescents <60 kg received 200 mg Q2W after a 400 mg loading dose.1

VIEW ADOLESCENT Study Design VIEW ADOLESCENT IGA RESULTS

Itch data post hoc analysis4

AD-1526 12-17 YEARS

MEAN CHANGE IN DAILY PEAK PRURITUS NRS FROM BASELINE AT DAY 15
(post hoc analysis)4

Limitations of analysis:
  • The prespecified itch endpoint in AD-1526 used weekly averaged Peak Pruritus NRS; this post hoc analysis is based on daily Peak Pruritus NRS4
  • Definitive conclusions cannot be made as this daily Peak Pruritus analysis (compared with weekly averaged analysis) was post hoc and was not statistically powered in this trial4
View Adolescent Study Design VIEW ADOLESCENT IGA RESULTS

LSM, least squares mean.

aFull Analysis Set includes all subjects randomized.1

bIn the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders (59% and 21% in the placebo and DUPIXENT arms, respectively).1

Explore more Peak Pruritus NRS efficacy results

VIEW ADULT DATA VIEW INFANT TO PRESCHOOLER
(6 MONTHS TO 5 YEARS) DATA VIEW CHILD (6 TO 11 YEARS) DATA VIEW AD WITH HAND AND/OR FOOT INVOLVEMENT DATA
(AGES 12+ YEARS)

Peak Pruritus NRS assesses the average itch intensity over the previous 24 hours5

It is a patient-reported measure that uses a 0- to 10-point scale, with which patients are asked:

“On a scale of 0 to 10, how would you rate your itch overall (on average) during the previous 24 hours?”

0

1

2

3

4

5

6

7

8

9

A reduction of at least 4 points in Peak Pruritus NRS from baseline is a clinically meaningful change.1

READY TO
PRESCRIBE
DUPIXENT?

DOSAGE AND ADMINISTRATION